PPRT 211
Latest Information Update: 20 Feb 2008
At a glance
- Originator PharmaPrint
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 17 Mar 2003 No development reported - Preclinical for Insomnia in USA (unspecified route)
- 07 Sep 2001 The compound is still in active development
- 25 Nov 1998 Preclinical development for Insomnia in USA (Unknown route)